| 产品名称 | 产品编号 | CAS编号 | 分子式 = 分子量 | 位单 | 联系QQ |
| 8-epi-Chlorajapolide F; 8-epi-Chlorajapolide F | CFN91951 | 863301-69-3 | C16H20O4 = 276.33 | 5mg | QQ客服：1413575084 |
| 金粟兰内酯A; Chloranthalactone A | CFN91950 | 66395-02-6 | C15H16O2 = 228.29 | 5mg | QQ客服：2159513211 |
| 8beta,9alpha-Dihydroxylindan-4(5),7(11)-dien-8alpha,12-olide; 8beta,9alpha-Dihydroxylindan-4(5),7(11)-dien-8alpha,12-olide | CFN91948 | 956707-04-3 | C15H18O4 = 262.30 | 5mg | QQ客服：1457312923 |
| 伪新乌药醚内酯; Pseudoneolinderane | CFN91936 | 20082-45-5 | C15H16O4 = 260.29 | 5mg | QQ客服：3257982914 |
| Strychnistenolide; Strychnistenolide | CFN91933 | 332372-09-5 | C15H18O4 = 262.30 | 5mg | QQ客服：2159513211 |
| 乌药醇乙酸酯; Linderene acetate | CFN91930 | 26146-28-1 | C17H20O3 = 272.34 | 5mg | QQ客服：2056216494 |
| 二氢焦蓬莪术酮; Dihydropyrocurzerenone | CFN91911 | 59462-26-9 | C15H18O = 214.30 | 5mg | QQ客服：2159513211 |
| 锦鸡菊素; Helenalin | CFN91899 | 6754-13-8 | C15H18O4 = 262.30 | 5mg | QQ客服：2056216494 |
| 别土木香内酯; Alloalantolactone | CFN91880 | 64340-41-6 | C15H20O2 = 232.32 | 10mg | QQ客服：1413575084 |
| 没药当归烯酮; Bisabolangelone | CFN91876 | 30557-81-4 | C15H20O3 = 248.32 | 10mg | QQ客服：1413575084 |
| 甘松新酮二醇; Nardosinonediol | CFN89546 | 20489-11-6 | C15H24O3 = 252.34 | 5mg | QQ客服：215959384 |
| 辛辣内酯A; Pungiolide A | CFN80472 | 130395-54-9 | C30H36O7 = 508.6 | 5mg | QQ客服：3257982914 |
| 蕨苷A; Pteroside A | CFN80184 | 35910-15-7 | C21H30O8 = 410.19 | 5mg | QQ客服：1413575084 |
| 蕨素A; Pterosin A | CFN80051 | 35910-16-8 | C15H20O3 = 248.14 | 5mg | QQ客服：215959384 |
| 原蕨苷; Ptaquiloside | CFN80061 | 87625-62-5 | C20H30O8 = 398.19 | 5mg | QQ客服：2159513211 |
Cell. 2018 Jan 11;172(1-2):249-261.e12. doi: 10.1016/j.cell.2017.12.019.IF=36.216(2019)
Cell Metab. 2020 Mar 3;31(3):534-548.e5. doi: 10.1016/j.cmet.2020.01.002.IF=22.415(2019)
Mol Cell. 2017 Nov 16;68(4):673-685.e6. doi: 10.1016/j.molcel.2017.10.022.IF=14.548(2019)
ACS Nano. 2018 Apr 24;12(4): 3385-3396. doi: 10.1021/acsnano.7b08969.IF=13.903(2019)
Nature Plants. 2016 Dec 22;3: 16206. doi: 10.1038/nplants.2016.205.IF=13.297(2019)
Sci Adv. 2018 Oct 24;4(10): eaat6994. doi: 10.1126/sciadv.aat6994.IF=12.804(2019)